A 52-year-old postmenopausal woman presents with abdominal distension and ascites. Imaging reveals a large ovarian mass with mixed solid and cystic components. Histopathology shows glandular structures lined by tall columnar mucin-secreting cells with areas of necrosis. Regarding this tumor, all of the following are true EXCEPT:

Explanation

## Mucinous Epithelial Ovarian Tumors — Clinical and Prognostic Features ### Case Analysis The histology described (tall columnar mucin-secreting cells, glandular structures) is diagnostic of **mucinous adenocarcinoma** of the ovary. The clinical presentation (postmenopausal, ascites, mixed solid-cystic mass) is typical. **Key Point:** Mucinous ovarian tumors have WORSE prognosis than serous tumors when stage-matched, not better. This is the critical error in option 2. ### Why Mucinous Tumors Have Worse Prognosis 1. **Stage-for-stage comparison:** Mucinous carcinomas show lower 5-year survival than serous carcinomas at equivalent stages 2. **Advanced presentation:** Often present at stage III–IV 3. **Chemotherapy resistance:** Mucinous histology is associated with reduced platinum sensitivity 4. **Molecular biology:** Different mutation profiles (KRAS mutations more common) compared to serous tumors ### Correct Statements Explained **Unilateral Presentation & Bilateral Concern** - Mucinous tumors are unilateral in >95% of cases - Bilateral mucinous ovarian masses = metastatic disease (appendiceal, colonic primary) until proven otherwise - Careful examination of appendix and colon is mandatory in bilateral cases **Tumor Markers** - **CA 19-9 and CEA** are elevated in mucinous tumors (60–80% of cases) - **CA-125** is less sensitive for mucinous histology (elevated in only 30–40%) - This marker profile helps distinguish mucinous from serous tumors (serous: CA-125 >> CA 19-9) **Embryologic Origin** - Mucinous tumors arise from **müllerian duct remnants** (coelomic epithelium) - Serous tumors also arise from müllerian ducts - Both are müllerian-derived; this statement is correct **Rupture & Pseudomyxoma Peritonei (PMP)** - Rupture of mucinous tumors can seed peritoneum with mucin-producing cells - Results in **pseudomyxoma peritonei** — gelatinous ascites with peritoneal implants - This is a serious intraoperative complication requiring careful handling - Appendiceal mucinous neoplasms are a more common source of PMP than ovarian tumors | Feature | Serous | Mucinous | | --- | --- | --- | | Frequency | 40% | 20% | | Bilaterality | 15–20% | <5% | | CA-125 elevation | 80–90% | 30–40% | | CA 19-9/CEA elevation | 10–20% | 60–80% | | 5-year survival (stage I) | 90% | 85% | | 5-year survival (stage III) | 30% | 20% | | Chemotherapy response | Better | Worse | | PMP risk | Low | Moderate | **High-Yield:** Mucinous tumors = worse prognosis than serous (stage-matched), unilateral, CA 19-9/CEA positive, PMP risk on rupture. **Mnemonic:** **MUCIN** — **M**ucinous tumors are **U**nilateral, **C**EA/CA19-9 elevated, **I**nferior prognosis (vs serous), **N**eed appendix examination if bilateral. **Clinical Pearl:** Always inspect the appendix in cases of bilateral mucinous ovarian masses or when mucinous ovarian tumor is found — appendiceal mucinous neoplasms can metastasize to the ovary and are the true primary in many cases.